Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents
During the past decade, significant therapeutic progress has been made in the field of allergic diseases, mainly concerning the pathogenic role of type 2 inflammation. Biologics targeting specific key cytokines, such as interleukin (IL)-4, IL-5, and IL-13, as well as IgE, have emerged as promising i...
Gespeichert in:
| Veröffentlicht in: | Paediatric drugs 2020-06, Vol.22 (3), p.295-310 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 310 |
|---|---|
| container_issue | 3 |
| container_start_page | 295 |
| container_title | Paediatric drugs |
| container_volume | 22 |
| creator | Licari, Amelia Castagnoli, Riccardo Marseglia, Alessia Olivero, Francesca Votto, Martina Ciprandi, Giorgio Marseglia, Gian Luigi |
| description | During the past decade, significant therapeutic progress has been made in the field of allergic diseases, mainly concerning the pathogenic role of type 2 inflammation. Biologics targeting specific key cytokines, such as interleukin (IL)-4, IL-5, and IL-13, as well as IgE, have emerged as promising innovative therapies for allergic disorders. In this context, dupilumab has emerged as one of the most successful therapies targeting the IL-4R axis. Dupilumab is a human IgG4 antibody anti-IL-4 receptor (IL-4R) α-subunit that blocks IL‐4R signaling induced by both IL‐4 and IL‐13, downregulating the molecular pathways that drive type 2 inflammatory diseases, including atopic dermatitis, allergic rhinitis, allergic asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. This review presents the most recent evidence on dupilumab for the treatment of type 2 inflammatory diseases and discusses the future perspective, focusing on the pediatric age group and adolescents. |
| doi_str_mv | 10.1007/s40272-020-00387-2 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2412503531</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A714588619</galeid><sourcerecordid>A714588619</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-b523f927a5d7acce9b815f59cc87c3279c0fd61ec27a51999908f7ba6652b5933</originalsourceid><addsrcrecordid>eNp9kc1u3CAURlHVqEnTvkAWFVLWTuFijFmOJj-NGimb6RphfEmIbDwFezFvHzKTNqoUFRZcwfkuoEPIGWcXnDH1PdcMFFQMWMWYaFUFH8gJ50pXwLj-uK_rSraqPSafc35ijCvRwCdyLIBLJaU4IT8vl20YltF2dJ7oJqGd6Wa3RQr0NvrBjqOdp7SjlyGjzZhpiHT9GIY-YaQ29nTVTwNmh3HOX8iRt0PGr6_rKfl1fbVZ_6ju7m9u16u7ytU1zFUnQXgNyspeWedQdy2XXmrnWuUEKO2Y7xuO7gXhugzWetXZppHQSS3EKTk_9N2m6feCeTZP05JiudJAzUEyIQV_ox7sgCZEP83JujFkZ1aK17JtG64LdfEOVWaPY3BTRB_K_j8BOARcmnJO6M02hdGmneHMvGgxBy2maDF7LQZK6Nvri5duxP5v5I-HAogDkMtRfMD09qX_tH0GQAuU7g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2412503531</pqid></control><display><type>article</type><title>Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents</title><source>Springer Nature - Complete Springer Journals</source><creator>Licari, Amelia ; Castagnoli, Riccardo ; Marseglia, Alessia ; Olivero, Francesca ; Votto, Martina ; Ciprandi, Giorgio ; Marseglia, Gian Luigi</creator><creatorcontrib>Licari, Amelia ; Castagnoli, Riccardo ; Marseglia, Alessia ; Olivero, Francesca ; Votto, Martina ; Ciprandi, Giorgio ; Marseglia, Gian Luigi</creatorcontrib><description>During the past decade, significant therapeutic progress has been made in the field of allergic diseases, mainly concerning the pathogenic role of type 2 inflammation. Biologics targeting specific key cytokines, such as interleukin (IL)-4, IL-5, and IL-13, as well as IgE, have emerged as promising innovative therapies for allergic disorders. In this context, dupilumab has emerged as one of the most successful therapies targeting the IL-4R axis. Dupilumab is a human IgG4 antibody anti-IL-4 receptor (IL-4R) α-subunit that blocks IL‐4R signaling induced by both IL‐4 and IL‐13, downregulating the molecular pathways that drive type 2 inflammatory diseases, including atopic dermatitis, allergic rhinitis, allergic asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. This review presents the most recent evidence on dupilumab for the treatment of type 2 inflammatory diseases and discusses the future perspective, focusing on the pediatric age group and adolescents.</description><identifier>ISSN: 1174-5878</identifier><identifier>EISSN: 1179-2019</identifier><identifier>DOI: 10.1007/s40272-020-00387-2</identifier><identifier>PMID: 32157553</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Allergic reaction ; Allergy ; Antibodies ; Asthma ; Children ; Chronic illnesses ; Cytokines ; Dermatitis ; Disease ; Diseases ; Drug therapy ; Esophagitis ; Immunotherapy ; Inflammation ; Inflammatory diseases ; Internal Medicine ; Medicine ; Medicine & Public Health ; Monoclonal antibodies ; Pediatric research ; Pediatrics ; Pharmacotherapy ; Recruitment ; Review Article ; Skin ; Teenagers</subject><ispartof>Paediatric drugs, 2020-06, Vol.22 (3), p.295-310</ispartof><rights>Springer Nature Switzerland AG 2020</rights><rights>COPYRIGHT 2020 Springer</rights><rights>Copyright Springer Nature B.V. Jun 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-b523f927a5d7acce9b815f59cc87c3279c0fd61ec27a51999908f7ba6652b5933</citedby><cites>FETCH-LOGICAL-c442t-b523f927a5d7acce9b815f59cc87c3279c0fd61ec27a51999908f7ba6652b5933</cites><orcidid>0000-0002-1773-6482 ; 0000-0001-7016-8421 ; 0000-0003-0029-9383 ; 0000-0003-3662-0159</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40272-020-00387-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40272-020-00387-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27915,27916,41479,42548,51310</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32157553$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Licari, Amelia</creatorcontrib><creatorcontrib>Castagnoli, Riccardo</creatorcontrib><creatorcontrib>Marseglia, Alessia</creatorcontrib><creatorcontrib>Olivero, Francesca</creatorcontrib><creatorcontrib>Votto, Martina</creatorcontrib><creatorcontrib>Ciprandi, Giorgio</creatorcontrib><creatorcontrib>Marseglia, Gian Luigi</creatorcontrib><title>Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents</title><title>Paediatric drugs</title><addtitle>Pediatr Drugs</addtitle><addtitle>Paediatr Drugs</addtitle><description>During the past decade, significant therapeutic progress has been made in the field of allergic diseases, mainly concerning the pathogenic role of type 2 inflammation. Biologics targeting specific key cytokines, such as interleukin (IL)-4, IL-5, and IL-13, as well as IgE, have emerged as promising innovative therapies for allergic disorders. In this context, dupilumab has emerged as one of the most successful therapies targeting the IL-4R axis. Dupilumab is a human IgG4 antibody anti-IL-4 receptor (IL-4R) α-subunit that blocks IL‐4R signaling induced by both IL‐4 and IL‐13, downregulating the molecular pathways that drive type 2 inflammatory diseases, including atopic dermatitis, allergic rhinitis, allergic asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. This review presents the most recent evidence on dupilumab for the treatment of type 2 inflammatory diseases and discusses the future perspective, focusing on the pediatric age group and adolescents.</description><subject>Allergic reaction</subject><subject>Allergy</subject><subject>Antibodies</subject><subject>Asthma</subject><subject>Children</subject><subject>Chronic illnesses</subject><subject>Cytokines</subject><subject>Dermatitis</subject><subject>Disease</subject><subject>Diseases</subject><subject>Drug therapy</subject><subject>Esophagitis</subject><subject>Immunotherapy</subject><subject>Inflammation</subject><subject>Inflammatory diseases</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Monoclonal antibodies</subject><subject>Pediatric research</subject><subject>Pediatrics</subject><subject>Pharmacotherapy</subject><subject>Recruitment</subject><subject>Review Article</subject><subject>Skin</subject><subject>Teenagers</subject><issn>1174-5878</issn><issn>1179-2019</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kc1u3CAURlHVqEnTvkAWFVLWTuFijFmOJj-NGimb6RphfEmIbDwFezFvHzKTNqoUFRZcwfkuoEPIGWcXnDH1PdcMFFQMWMWYaFUFH8gJ50pXwLj-uK_rSraqPSafc35ijCvRwCdyLIBLJaU4IT8vl20YltF2dJ7oJqGd6Wa3RQr0NvrBjqOdp7SjlyGjzZhpiHT9GIY-YaQ29nTVTwNmh3HOX8iRt0PGr6_rKfl1fbVZ_6ju7m9u16u7ytU1zFUnQXgNyspeWedQdy2XXmrnWuUEKO2Y7xuO7gXhugzWetXZppHQSS3EKTk_9N2m6feCeTZP05JiudJAzUEyIQV_ox7sgCZEP83JujFkZ1aK17JtG64LdfEOVWaPY3BTRB_K_j8BOARcmnJO6M02hdGmneHMvGgxBy2maDF7LQZK6Nvri5duxP5v5I-HAogDkMtRfMD09qX_tH0GQAuU7g</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Licari, Amelia</creator><creator>Castagnoli, Riccardo</creator><creator>Marseglia, Alessia</creator><creator>Olivero, Francesca</creator><creator>Votto, Martina</creator><creator>Ciprandi, Giorgio</creator><creator>Marseglia, Gian Luigi</creator><general>Springer International Publishing</general><general>Springer</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0002-1773-6482</orcidid><orcidid>https://orcid.org/0000-0001-7016-8421</orcidid><orcidid>https://orcid.org/0000-0003-0029-9383</orcidid><orcidid>https://orcid.org/0000-0003-3662-0159</orcidid></search><sort><creationdate>20200601</creationdate><title>Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents</title><author>Licari, Amelia ; Castagnoli, Riccardo ; Marseglia, Alessia ; Olivero, Francesca ; Votto, Martina ; Ciprandi, Giorgio ; Marseglia, Gian Luigi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-b523f927a5d7acce9b815f59cc87c3279c0fd61ec27a51999908f7ba6652b5933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Allergic reaction</topic><topic>Allergy</topic><topic>Antibodies</topic><topic>Asthma</topic><topic>Children</topic><topic>Chronic illnesses</topic><topic>Cytokines</topic><topic>Dermatitis</topic><topic>Disease</topic><topic>Diseases</topic><topic>Drug therapy</topic><topic>Esophagitis</topic><topic>Immunotherapy</topic><topic>Inflammation</topic><topic>Inflammatory diseases</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Monoclonal antibodies</topic><topic>Pediatric research</topic><topic>Pediatrics</topic><topic>Pharmacotherapy</topic><topic>Recruitment</topic><topic>Review Article</topic><topic>Skin</topic><topic>Teenagers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Licari, Amelia</creatorcontrib><creatorcontrib>Castagnoli, Riccardo</creatorcontrib><creatorcontrib>Marseglia, Alessia</creatorcontrib><creatorcontrib>Olivero, Francesca</creatorcontrib><creatorcontrib>Votto, Martina</creatorcontrib><creatorcontrib>Ciprandi, Giorgio</creatorcontrib><creatorcontrib>Marseglia, Gian Luigi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Paediatric drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Licari, Amelia</au><au>Castagnoli, Riccardo</au><au>Marseglia, Alessia</au><au>Olivero, Francesca</au><au>Votto, Martina</au><au>Ciprandi, Giorgio</au><au>Marseglia, Gian Luigi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents</atitle><jtitle>Paediatric drugs</jtitle><stitle>Pediatr Drugs</stitle><addtitle>Paediatr Drugs</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>22</volume><issue>3</issue><spage>295</spage><epage>310</epage><pages>295-310</pages><issn>1174-5878</issn><eissn>1179-2019</eissn><abstract>During the past decade, significant therapeutic progress has been made in the field of allergic diseases, mainly concerning the pathogenic role of type 2 inflammation. Biologics targeting specific key cytokines, such as interleukin (IL)-4, IL-5, and IL-13, as well as IgE, have emerged as promising innovative therapies for allergic disorders. In this context, dupilumab has emerged as one of the most successful therapies targeting the IL-4R axis. Dupilumab is a human IgG4 antibody anti-IL-4 receptor (IL-4R) α-subunit that blocks IL‐4R signaling induced by both IL‐4 and IL‐13, downregulating the molecular pathways that drive type 2 inflammatory diseases, including atopic dermatitis, allergic rhinitis, allergic asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. This review presents the most recent evidence on dupilumab for the treatment of type 2 inflammatory diseases and discusses the future perspective, focusing on the pediatric age group and adolescents.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32157553</pmid><doi>10.1007/s40272-020-00387-2</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-1773-6482</orcidid><orcidid>https://orcid.org/0000-0001-7016-8421</orcidid><orcidid>https://orcid.org/0000-0003-0029-9383</orcidid><orcidid>https://orcid.org/0000-0003-3662-0159</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1174-5878 |
| ispartof | Paediatric drugs, 2020-06, Vol.22 (3), p.295-310 |
| issn | 1174-5878 1179-2019 |
| language | eng |
| recordid | cdi_proquest_journals_2412503531 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Allergic reaction Allergy Antibodies Asthma Children Chronic illnesses Cytokines Dermatitis Disease Diseases Drug therapy Esophagitis Immunotherapy Inflammation Inflammatory diseases Internal Medicine Medicine Medicine & Public Health Monoclonal antibodies Pediatric research Pediatrics Pharmacotherapy Recruitment Review Article Skin Teenagers |
| title | Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T04%3A21%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dupilumab%20to%20Treat%20Type%202%20Inflammatory%20Diseases%20in%20Children%20and%20Adolescents&rft.jtitle=Paediatric%20drugs&rft.au=Licari,%20Amelia&rft.date=2020-06-01&rft.volume=22&rft.issue=3&rft.spage=295&rft.epage=310&rft.pages=295-310&rft.issn=1174-5878&rft.eissn=1179-2019&rft_id=info:doi/10.1007/s40272-020-00387-2&rft_dat=%3Cgale_proqu%3EA714588619%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2412503531&rft_id=info:pmid/32157553&rft_galeid=A714588619&rfr_iscdi=true |